Immunotherapeutic strategies, especially those targeting the Galectin-9/Tim-3/Foxp3 interaction, may serve as the potential salvage treatments for recurrent NPC33 in recurrent NPC. This evidence concerns the gene HAVCR2 and nasopharyngeal carcinoma.